Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system

Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system

BackgroundRisankizumab, a humanized IgG1 monoclonal antibody that selectively inhibits IL-23, is currently approved for the treatment of moderate-to-severe plaque psoriasis and Crohn’s disease. The real-world safety study of risankizumab in a large- sample population is currently lacking. The aim of...

Full description

Bibliographic Details
Main Authors: Yamin Shu, Jing Chen, Yiling Ding, Qilin Zhang
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-05-01
Series:Frontiers in Immunology
Subjects:
adverse event
disproportionality
FAERS
pharmacovigilance
risankizumab
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1169735/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1169735/full

Similar Items